Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1474368 | 1.00 | IMPDH2 (0.73) | IMPDH2AAK1 | |
| SCHEMBL5529251 | 0.94 | IMPDH2 (0.69) | IMPDH2AAK1 | |
| SCHEMBL5613866 | 0.88 | IMPDH2 (0.66) | IMPDH2AAK1 | |
| SCHEMBL1473474 | 0.84 | IMPDH2 (0.66) | IMPDH2AAK1 | |
| SCHEMBL1473477 | 0.84 | IMPDH2 (0.66) | IMPDH2AAK1 | |
| SCHEMBL5526294 | 0.84 | IMPDH2 (0.61) | IMPDH2AAK1 | |
| SCHEMBL1473834 | 0.83 | IMPDH2 (0.64) | IMPDH2 | |
| SCHEMBL1473831 | 0.83 | IMPDH2 (0.64) | IMPDH2 | |
| SCHEMBL5614013 | 0.82 | IMPDH2 (0.64) | IMPDH2 | |
| SCHEMBL16239574 | 0.82 | IMPDH2 (0.63) | IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6420403-B1 | INOSINE-5'-MONOPHOSPHATE DEHYDROGENASE, TRANSPLANT REJECTION AND AUTOIMMUNE DISEASES. | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-16 | — | — | US | claimed |
| EP-2803357-B1 | Angiogenesis inhibitors | UNIV JOHNS HOPKINS (US) | 2020-11-18 | — | — | EP | disclosed |
| US-8980930-B2 | Angiogenesis inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| EP-2803357-A2 | Angiogenesis inhibitors | THE JOHNS-HOPKINS UNIVERSITY (US) | 2014-11-19 | — | — | EP | disclosed |
| US-20130101657-A1 | ANGIOGENESIS INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-04-25 | — | — | US | disclosed |
| US-7915255-B2 | Metabolism-modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2011-03-29 | — | — | US | disclosed |
| US-20080193499-A1 | Angiogenesis Inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1786415-A1 | METABOLISM-MODULATING AGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-05-23 | — | — | EP | disclosed |
| EP-1765336-A2 | ANGIOGENESIS INHIBITORS | THE JOHNS-HOPKINS UNIVERSITY (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060106097-A1 | Metabolism-modulating agents and uses therefor | UNIVERSITY OF QUEENSLAND (AU) | 2006-05-18 | — | — | US | disclosed |
| WO-2006017896-A1 | METABOLISM-MODULATING AGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006004795-A2 | ANGIOGENESIS INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-01-12 | — | — | WO | disclosed |
| US-6420403-B1 | INOSINE-5'-MONOPHOSPHATE DEHYDROGENASE, TRANSPLANT REJECTION AND AUTOIMMUNE DISEASES. | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193499-A1 | Angiogenesis Inhibitors | FLT1, VEGFA, FLT4 | IMPDH2 2862/4885AAK1 793/4885 |
| US-20130101657-A1 | ANGIOGENESIS INHIBITORS | FLT1, VEGFA, FLT4 | IMPDH2 2862/4885AAK1 793/4885 |
| US-20060106097-A1 | Metabolism-modulating agents and uses therefor | IMPDH1, IMPDH2, HADHB | IMPDH2 2/4885AAK1 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.